Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HCW9218 |
Synonyms | |
Therapy Description |
HCW9218 is a fusion protein complex composed of TGFBR2 extracellular domains, a variant of IL15, and IL15RA sushi domains, which binds to and sequesters TGFB1, reducing downstream signaling and potentially increases antitumor immune response and tumor cell death (PMID: 34091051, PMID: 35051615). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HCW9218 | HCW-9218|HCW 9218 | HCW9218 is a fusion protein complex composed of TGFBR2 extracellular domains, a variant of IL15, and IL15RA sushi domains, which binds to and sequesters TGFB1, reducing downstream signaling and potentially increases antitumor immune response and tumor cell death (PMID: 34091051, PMID: 35051615). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05304936 | Phase Ib/II | HCW9218 | HCW9218 for Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT05322408 | Phase I | HCW9218 | HCW9218 in Select Advanced Solid Tumors | Active, not recruiting | USA | 0 |